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Abstract Bone morphogenetic proteins (BMPs) have been
implicated in the control of proliferation, tissue formation,
and differentiation. BMPs regulate the biology of stem and
progenitor cells and can promote cellular differentiation,
depending on the cell type and context. Although the BMP
pathway is known to be involved in early embryonic devel-
opment of the mammary gland via mesenchymal cells, its
role in later epithelial cellular differentiation has not been
examined. The majority of the mammary gland develop-
ment occurs post-natal, and its final functional differentia-
tion is characterized by the emergence of alveolar cells that
produce milk proteins. Here, we tested the hypothesis that
bone morphogenetic protein receptor 1A (BMPR1A) func-
tion was required for mammary epithelial cell differentia-
tion. We found that the BMPR1A-SMAD1/5/8 pathway was
predominantly active in undifferentiated mammary epitheli-
al cells, compared with differentiated cells. Reduction of
BMPR1A mRNA and protein, using short hairpin RNA,
resulted in a reduction of SMAD1/5/8 phosphorylation in
undifferentiated cells, indicating an impact on this pathway.
When the expression of the BMPR1A gene knocked down
in undifferentiated cells, this also prevented beta-casein pro-
duction during differentiation of the mammary epithelial cells
by lactogenic hormone stimulation. Addition of Noggin, a
BMP antagonist, also prevented beta-casein expression.
Together, this demonstrated that BMP-BMPR1A-SMAD1/
5/8 signal transduction is required for beta-casein produc-
tion, a marker of alveolar cell differentiation. This evidence
functionally identifies BMPR1A as a potential new regula-
tor of mammary epithelial alveolar cell differentiation.
Keywords Bone morphogenetic protein receptor-1A .
SMAD .Mammary epithelial cells . HC11 cells .
Differentiation . Short interfering RNA . Prolactin . Noggin
Introduction
In addition to the roles of the bone morphogenetic protein
(BMP) pathway controlling cell fate in embryonic stem
cells, it has tissue-specific roles in epithelial stem cell main-
tenance and progenitor cell differentiation in the hair follicle
(Kobielak et al. 2003; Guha et al. 2004; Zhang et al. 2006),
prevents premature differentiation of myogenic satellite
cells (Ono et al. 2011), and a role in adipocyte lineage
determination from stem cells (Huang et al. 2009). Given
these roles, we investigated its requirement for mammary
epithelial cell differentiation.
BMPs bind to a complex of types 1 (bone morphogenetic
protein receptor 1A (BMPR1A) and BMPR1B) and 2
(BMPR2) receptors, leading to phosphorylation of the type
1 receptors by the kinase domain of the type 2 receptors.
Activation of the canonical pathway results in phosphoryla-
tion of specific SMAD proteins such as SMAD1, SMAD5
and SMAD8 (SMAD1/5/8). These complex with co-
SMAD4 and translocate to the nucleus to affect gene regu-
lation. Type 1 receptors dictate the specificity of ligand
binding, and in the case of BMPR1A, it is BMP 2, BMP4,
and to a lesser extent BMP7 (Botchkarev 2003).
The role of the BMP pathway is implicated in early
mammary gland development. BMP4 is known to be im-
portant in ductal growth during embryonic mammary gland
development, with the BMPR1A (also known as activin-like
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kinase 3) playing a role in the mammary mesenchyme, as
opposed to the epithelium (Hens et al. 2007). BMP4 was
also able to potentiate fibroblast growth factor (FGF)-2-,
FGF-7-, FGF-10-, epidermal growth factor (EGF)-, or he-
patocyte growth factor-induced cellular proliferation in
J3B1A mammary epithelial cells, although BMP4 did not
affect proliferation on its own (Montesano et al. 2008). In
3D collagen cultures of J3B1A cells, BMP4 disrupted spon-
taneous cellular morphology of polarized acinar structures
in a pathway dependent on mitogen-activated protein
kinases (Montesano 2007). The role of the BMP pathway
in lactogenic mammary cell differentiation has not yet been
examined.
It is believed that lactogenic mammary epithelial cells
differentiate from luminal progenitors (Welm et al. 2002;
Shackleton et al. 2006; Sleeman et al. 2006; Stingl et al.
2006; Asselin-Labat et al. 2007). HC11 cells, a prolactin
responsive clone of the COMMA-1D mouse (Balb/c) mam-
mary epithelial cell line, (Ball et al. 1988) have been used as
an in vitro model to study mammary epithelial cell differ-
entiation of the luminal lineage. HC11 cells are a well-
known cell line that can be cultured to represent undiffer-
entiated cells (with EGF and insulin), competent to differ-
entiate (EGF), and differentiated (dexamethasone, insulin,
and prolactin) cells. Competent cells (cultured in EGF) can
be pre-differentiated with the lactogenic hormones dexa-
methasone and insulin prior to treatment with prolactin,
which stimulates HC11 cells to produce markers of alveolar
cell differentiation (Desrivieres et al. 2003; Perotti et al.
2009) including beta-casein. Previously, we identified
Bmpr1a in a screen designed to identify potential regulators
of differentiation, as a gene that was preferentially expressed
in undifferentiated HC11 cells compared with differentiated
HC11 cells (Perotti et al. 2009). We hypothesize that a
reduction in BMPR1A signaling would disturb mammary
epithelial progenitor cell differentiation. We now demon-
strate that BMPR1A activity in HC11 mammary epithelial
cells is required prior to lactogenic signal transduction, for
the stage of milk-secretory cell differentiation marked by
beta-casein production.
Materials and Methods
Antibodies. Goat and rabbit anti BMPR1A antibodies were
purchased from Santa Cruz (Santa Cruz, CA) and Abgent
(Biolynx, San Diego, CA), respectively. Goat anti beta-
casein (M-14) was obtained from Santa Cruz. Mouse anti-
GRB2 and anti-phospho-SMAD1/5/8 (SMAD1,5 phospho-
Ser 463/465, SMAD8 phospho-Ser 426/428) antibodies
were purchased from Cell Signaling Technology (Pickering,
ON, Canada), Histone H3 from Millipore (Billerica, MA).
Secondary antibodies, HRP conjugated, were obtained from
Bio-Rad (Mississauga, ON, Canada) and Pierce (Nepean,
ON, Canada), fluorescence conjugated from Invitrogen
(Burlington, ON, Canada).
Materials. RPMI 1640 medium was purchased from
Hyclone (Nepean, ON, Canada). Glutamine, penicillin/
streptomycin, and trypsin were from Gibco-Invitrogen.
Insulin (bovine) and prolactin (ovine) were from Sigma
(Oakville, ON, Canada), and EGF (mouse) from BD
Biosciences (Mississauga, ON, Canada). The recombi-
nant human Noggin/Fc chimera was purchased from
R&D Systems (Minneapolis, MN).
Cell culture. Mouse HC11 cells (Ball et al. 1988) were
grown in RPMI 1640 medium containing 10 % fetal
calf serum, 2 mM L-glutamine and 100 units/ml peni-
cillin–streptomycin. For cell maintenance, the medium
was supplemented with insulin 5 μg/ml and EGF
0.01 μg/ml.
Differentiation of HC11 cells. For differentiation, 0.7×105
HC11 undifferentiated cells/ml were cultured in 100 mm
dishes during 4 d in RPMI media (+5 μg/ml insulin+10 μg/
ml EGF). During this time cells reached 100 % conflu-
ence. Cells were then washed with PBS three times and
media was replaced with competence media (+EGF)
and were maintained for 1 d, after which they become
responsive to lactogenic hormones. Then cells were
washed and pre-differentiation media was added (+in-
sulin+dexamethasone 10−7 M) for 1 d. Finally, cells
were cultured for 3 d in differentiation media (+insu-
lin+dexamethasone+prolactin 5 μg/ml) (Perotti et al.
2009). If included in the experiment, Noggin was
added at the concentration indicated at the start of the
differentiation procedure. Differentiation was monitored
by measuring beta-casein production, using western blot
and PCR.
Protein extracts. The cells taken at the appropriate time for
undifferentiated, competent and differentiated stages were
scraped with a rubber policeman in PBS on ice, centrifuged
at 4°C and resuspended in NP40 lysis buffer, containing a
set of protease inhibitors, 20 mM Tris-HCl, 150 mM NaCl,
2 mM EDTA, 0.1 % Triton-X, and 1 % SDS (Perotti et al.
2009). From the supernatant, 50 μg of protein was loaded
per lane. Detection of fluorophores on the Odyssey (Licor)
using fluorescent antibodies or on film with horse-radish
peroxidase-labeled secondary antibodies was performed.
Nuclear extracts were prepared as follows: soluble cytoplas-
mic extracts were prepared in a buffer containing 20 mM
HEPES at pH 7.9, 10 mM KCl, 1 mM EDTA, 0.2 % NP-40,
378 PEROTTI ET AL.
10 % glycerol with protease, and phosphatase inhibitors
followed by centrifugation (15,000×g). The nuclear pellet
was resuspended in a buffer containing 420 mM NaCl, 20 %
glycerol, 20 mM HEPES at pH 7.9, 10 mM KCl, 1 mM
EDTAwith protease, and phosphatase inhibitors for 30 min
4°C before centrifugation (15000×g). For western analysis,
15 μg of soluble nuclear extract was loaded per lane
and either actin (Huang et al. 2005; Shitashige et al.
2007; Dai et al. 2009) or histone H3 were used as loading
controls.
RNA extractions and reverse transcription. Total RNA was
then extracted using Qiagen (Toronto, ON, Caanda) RNA
Easy kit. The first strand cDNA was obtained by reverse
transcription of 20 μg RNA using Superscript II reverse
transcriptase (Invitrogen), according to manufacturer’s
protocol.
PCR reactions. PCR was carried out in ×1 PCR buffer
(200 mM Tris-HCl and 500 mM KCl) plus 3 mM MgCl,
200 nM primers, and 200 μM dNTPs as previously de-
scribed (Perotti et al. 2009).
Amplification of the SMADs were as follows using a
SMAD1 forward primer: 5′CGCTATGAATGTGAC-
CAGCTT3′, SMAD5 forward primer: 5′GAGTGGA-
GAGTCCAGTCTTACCT3′, SMAD8 forward primer: 5′
GTCACAGAGTATACACCAAGAAG3′ in the above con-
ditions for 28 cycles at 55°C.
shRNA preparation, transfection, and transduction. Four
different sequences of shRNA were prepared that targeted
different regions of the Bmpr1a mRNA (accession number
NM_009758). Sequences for shRNA starting at nucleotide
positions 1258, 823, and 348, of the BMPR1A gene were
obtained from Oligoengine. RNAi explorer from Gene Link
was used to create a shRNA starting at sequence 1124 and
lamin sequence design. The siRNAWizard (InvivoGen) was
used to create a scrambled sequence of the target identified
from the 1124 start position (shScr). The shRNA sequences
were cloned into pSuper.retro vector (Oligoengine) using
HindIII sites. HC11 cells were transfected with the shRNA
containing constructs or with the empty vector (EV) using
Lipofectamine 2000 (Invitrogen), according to manufac-
turer’s protocols and cells were selected using Geneticin
resistance to create several different clones of six cell lines
(shBMPR1A-1258, shBMPR1A-1124, shBMPR1A-823,
shBMPR1A-348, shEV, shLam, and shScr). Alternatively,
cells were transfected using polyethylenimine (PEI). A 1-
mg/ml solution of linear PEI MW25K (Polyscience Inc. cat.
no. 23966, Woodbridge, ON, Canada) was prepared in water
and neutralized with HCL. For each well of a six-well plate
with cells at 70–80 % confluence, 2 μg DNA and 8 μl PEI
were added to 200 μl serum-free RPMI and mixed by
vortexing. PEI/DNA/medium mixture was added to cells
after 10–15 min incubation for a total of 2 ml of medium.
Geneticin treatment of 500–700 μg/ml started after 24 h
with fresh media and continued for 10 d. Alternatively, the
vectors were transfected into a 293T-based packaging cell
line, Phi-NX, (developed by Dr. Garry Nolan, Stanford
University) and the HC11 cells transduced with viral par-
ticles according to the pSuper.retro instructions.







The BMPR1A pathway is only active in undifferentiated and
competent cells. BMPs are members of the TGF-β super-
family. Activated receptors phosphorylate the DNA-binding
proteins SMAD1/5/8, each of which can then heterodimer-
ize with SMAD4 and translocate to the nucleus to regulate
transcription of downstream target genes (Itoh et al. 2000).
As the activity and function of the BMPR1A pathway in
mammary epithelial cells is relatively uncharacterized, we
investigated the phosphorylation of SMAD1/5/8 as a read-
out of the canonical BMPR1A pathway in the presence of
serum.
The activation of the BMPR1A pathway in parental and
shBMPR1A-stable cell lines was assessed using an antibody
directed against phosphorylated-SMAD1/5/8. We deter-
mined that the pathway is active in undifferentiated (treated
with EGF and insulin), competent (treated with EGF), and
pre-differentiated (treated with dexamethasone and insulin)
parental HC11 cells but that the activity is greatly reduced in
the differentiated cells, which are those treated additionally
with prolactin (Fig. 1A).
Knockdown of Bmpr1a with short-hairpin RNA. In order to
characterize the function of BMPR1A, we knocked
down Bmpr1a expression in HC11 cells. We separately
transfected four different vector constructs, each encoding a
different short hairpin (shRNA) against Bmpr1a
(shBMPR1A) that targeted different regions of the gene,
creating a minimum of four separate stable HC11-
shBMPR1A cell lines (shBMPR1A-348, shBMPR1A-823,
shBMPR1A-1124, and shBMPR1A-1258), one with
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shRNA directed against lamin A (shLam), scrambled-sh1124
(shScr) and one empty vector line (shEV). The four distinct
shBMPR1A sequences and six cell lines were generated in
order to greatly reduce the chance of off-target effects. In
addition, we made several distinct stable cell line clones with
each of the constructs as experimental replicates. Overall, the
results in the study were consistent across the replicates and
each of the different shBMPR1A sequences, providing multi-
ple levels of experimental replication.
Bmpr1a gene expression was analyzed by PCR before
and after knockdown. Compared with the control cells,
HC11 cells expressing one of the four shBMPR1A con-
structs had greatly reduced amounts of Bmpr1a mRNA
(representative lines, Fig. 1B). HC11 cells expressing an
shRNA directed against the unrelated target gene, lamin,
did not have reduced Bmpr1a expression (Fig. 1B), provid-
ing an indication of specificity of the BMPR1A shRNA.
The level of knockdown in each stable cell line was con-
firmed prior to performing additional experiments.
The effect of knockdown on BMPR1A protein levels was
also investigated using western blot and portrayed with one
representative shRNA sequence, shBMPR1A-1258 (Fig. 1C).
The relative level of BMPR1A protein in shBMPR1A-1258,
was considerably reduced compared with the undifferentiated
parental cell line or empty vector control line.
The reduction of BMPR1A using shRNA (shBMPR1A-
1258 shown as representative of all lines) resulted in loss of
SMAD1/5/8 phosphorylation (Fig. 1D), indicating that this
pathway is no longer active and thus not functioning in either
the undifferentiated or competent cells, in addition to the differ-
entiated cells that already had reduced BMPR1A pathway acti-
vation as compared with the parental cell line or one carrying the
empty vector. This was consistent among all four shRNA
sequences directed against Bmpr1a. Although the phosphoryla-
tion of individual SMADs was not tested, SMAD1, SMAD5
and SMAD8 are each expressed in undifferentiated HC11 cells
and their gene expression unaffected by knockdown of
BMPR1A (Fig. 1E). The reduction in BMPR1A mRNA and
Figure 1. ShRNA directed against Bmpr1a reduces mRNA, protein,
and SMAD activation. A, Western analysis showing phosphorylated
SMAD1/5/8 (60 kDa), in nuclear extracts of undifferentiated (U),
competent (C), and pre-differentiated (P-D) cells but reduced in differ-
entiated HC11 cells (D). Actin is used as a loading control. B, The
expression of Bmpr1a was analyzed by PCR in four knock-down cell
lines, shBMPR1A-348, shBMPR1A-823, shBMPR1A-1124, and
shBMPR1A-1258, and compared with expression in control cell lines,
shScr, undifferentiated HC11, shLam, or empty vector (EV) cells.
Amplification of the gene encoding 18S rRNA was used as a loading
control. C, Analysis of BMPR1A protein (59 kDa) in shBMPR1A-
1258 by western using the loading control (GRB2, 24 kDa). D, Ab-
sence of phosphorylated SMAD1/5/8 at all stages, in nuclear extracts
of HC11 cells, stably expressing shBMPR1A-1258. E Expression of
SMAD1/5/8 in undifferentiated cells.
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protein by shRNA therefore results in the abrogation of endog-
enous canonical SMAD1/5/8 phosphorylation.
BMPR1A is required for mammary epithelial cell differentia-
tion. The BMP/BMPR1A signalling pathway can influence
cell behaviour in many different ways, and BMPs have been
identified as important cell fate regulators, required for the
differentiation of other epithelial cells such as hair follicle
cells.
To determine if the reduction in BMPR1A by shRNA
affected mammary epithelial differentiation, total RNA and
soluble proteins were extracted from each of the differenti-
ation stages of the BMPR1A knockdown cell lines together
with the control HC11 cell lines and we investigated the
expression of the terminal alveolar cell differentiation mark-
er, beta-casein. Using PCR analysis, it is apparent that there
is little to no beta-casein (Csn2) gene expression in three
independent clones of the representative shBMPR1A se-
quence, shBMPR1A-1258, that were treated with lactogenic
hormones, in contrast to the parental cell lines (Fig. 2A).
Additionally, there is little to no production of beta-casein
protein in the shBMPR1A-1258 clones (Fig. 2B) or in any
of the shBMPR1A cell lines and clones upon treatment with
lactogenic hormones (Fig. 2C). Multiple stable cell lines
carrying the same shRNA and as well, multiple cell lines
each with different shRNA sequences all directed against
Bmpr1a expression produced similar results. As a negative
control, the level of beta-casein was unaffected by stable
presence of the empty vector as compared with parental or
the shBMPR1A-1258 cells (Fig. 2D). These results indicate
the requirement of BMPR1A and SMAD1/5/8 activation,
prior to differentiation, for the ultimate differentiation of
mammary epithelial cells into milk-secreting alveolar cells.
Noggin antagonizes mammary epithelial cell differentia-
tion. To validate our observations, we also tested the effect
of the BMP antagonist, Noggin, on HC11 cell differentia-
tion. Noggin antagonizes BMP-2, BMP-4, and BMP-7,
preventing their interaction with the receptor (for review,
see Botchkarev 2003). Treatment of undifferentiated cells
with increasing doses of Noggin results in a severe decrease
of phospho-SMAD1/5/8 (Fig. 3A). When these cells were
induced to differentiate, there was no beta-casein production
compared with the control cells (Fig. 3B, C). Together, this
indicates that the BMP-BMPR1A pathway is important for
the phase of mammary epithelial cell differentiation charac-
terized by beta-casein production.
Discussion
We determined that in mouse HC11 cells, differentiation
into milk-producing cells was blocked with the loss the
BMPR1A pathway prior to differentiation. Our investiga-
tion into the function of BMPR1A in the differentiation of
Figure 2. BMPR1A is required prior to lactogenic signaling for the
production of beta-casein. A, The PCR amplification of beta-casein
(Csn2) from cDNA prepared from fully differentiated HC11 cells was
compared with shRNA expressing cells that were also similarly treated
with lactogenic hormones. Three independent cell lines of a represen-
tative shBMPR1A, sh1258, are shown. Amplification of 18s rRNA
was used as loading control. B, The presence of beta-casein (29 kDa)
was analyzed by western blot. Beta-casein production was assessed in
parental HC11 cells across three stages of differentiation as a positive
control and in shBMPR1A-HC11 cells treated similarly with
lactogenic hormones, with three independent replicates of cell lines
carrying shBMPR1A-1258. C, Western analysis, using the Odyssey
(fluorescent secondary antibody), of beta-casein production in fully
differentiated HC11 cells of the parental HC11 line was compared with
different shBMPR1A lines similarly treated. Each lane, represents
independent experiments. Overexposure reveals a faint signal in lane
2. D, Western analysis of undifferentiated and differentiated HC11 cells
or cells stably expressing the empty vector (EV) or shBMPR1A-1258
treated with lactogenic hormones. Overexposure reveals a faint signal
in lane 4.
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mammary epithelial cells is the first indication that it could
function later in mammary gland development in addition to
its role in embryonic mammary gland formation.
The present analysis was based upon our previous screen
to identify differentially expressed genes upon lactogenic
hormone stimulation that could potentially have a role in
regulating differentiation (Perotti et al. 2009). The gene for
BMPR1A was preferentially expressed in undifferentiated
cells, although the BMPR1A protein was present at all
stages of HC11 differentiation. In this report, we determined
that the BMPR1A-SMAD1/5/8 pathway is active in undif-
ferentiated and pre-differentiated cells, but not, or is greatly
reduced, in differentiated cells. It was previously reported
that the activity of the estrogen receptor differs during HC11
differentiation although the estrogen receptor is expressed at
all phases, potentially reflecting corepressor levels (Faulds
et al. 2004). Therefore differential regulation of signal trans-
duction pathways is possible across HC11 differentiation.
We demonstrated that the BMPR1A-SMAD1/5/8 path-
way is greatly reduced upon treatment with prolactin.
Prolactin is essential for lobuloalveolar differentiation
(Horseman et al. 1997; Brisken et al. 1999) and may nega-
tively affect the upstream BMPR1A-SMAD1/5/8 pathway.
Prolactin inhibition of upstream pathways has been previ-
ously reported for cross-talk of the prolactin pathway with
that of EGF (Haines et al. 2009). Disruption of BMPR1A
expression prior to differentiation, in undifferentiated mam-
mary epithelial cells and/or competence phases where ex-
tracellular matrix proteins are produced (Chammas et al.
1994), prevented cellular differentiation and beta-casein
production. This demonstrates a requirement of the
BMPR1A receptor for differentiation that is upstream of
lactogenic signaling, potentially that of insulin, dexametha-
sone and/or prolactin. BMPR1A is required for the func-
tional differentiation of mammary epithelial cells into milk-
producing cells. Additional studies are required to explore
the intricate cross-talk regulating these pathways.
Previous studies examined the phenotype of the condi-
tional Keratin-14-Cre-BMPR1A null mouse, which targeted
expression in the epithelial cells. The conditional nulls had
normal mammary glands at the embryonic stage (Andl et al.
2004), indicating that the deletion of BMPR1A in Keratin-
14 expressing cells has little effect on early mammary gland
development. The effects of conditional deletion of
BMPR1A at later stages of mammary gland development
were not examined. Keratin-14 expression is essentially
restricted to the basal cell layer of the mammary epithelium.
It is possible, however, that BMR1A functions in the lumi-
nal cell compartment to permit alveolar cell differentiation.
Our results are consistent with what is known about the role
of BMPR1A in other epithelial cells, such as hair follicles.
In mice, BMPR1A is required for differentiation of the inner
root sheath (Andl et al. 2004) and hair shaft (Kobielak et al.
2003; Andl et al. 2004).
Transgenic doxycycline-induced expression of a condi-
tional dominant-negative BMPR2 receptor in the mammary
carcinoma model, mouse mammary tumor virus polyoma
middle T antigen, did not result in disruption of mammary
gland formation, at least in adult mice. The glands were not
examined during pregnancy, and the endogenous BMPR2
receptors were still expressed in this mouse system. The
study did indicate a tumor-suppressive role for BMPR2
(Owens et al. 2012).
Recent studies have demonstrated that mutational inacti-
vation of BMP signaling pathways is critical to the patho-
genesis of sporadic and inherited human cancer. Inherited
inactivating mutations of both the Bmpr1-a/Alk3 type I
receptor and the SMAD4 signaling molecule cause familial
juvenile polyposis, an inherited gastrointestinal cancer pre-
disposition syndrome (Howe et al. 1998; Howe et al. 2001)
(Zhou et al. 2001; Waite and Eng 2003). There is currently
little knowledge about BMP ligand and receptor function in
breast cancer. BMP6 has been detected in some breast
Figure 3. The BMP antagonist, Noggin, reduces SMAD1/5/8 phos-
phorylation and abrogates beta-casein production. A, Western analysis
of SMAD1/5/8 phosphorylation from nuclear extracts in the presence
of increasing doses of Noggin (in nanograms per milliliter). Histone
H3 is a loading control. B, Western analysis of beta-casein production
in HC11 cells cultured in the presence or absence of Noggin (2,000 ng/
ml) in their undifferentiated through to their differentiated state. C,
Westerns for beta-casein production in experimental replicates of
HC11 cells treated or not with Noggin from their undifferentiated to
differentiated state. Undifferentiated (U), competent (C), differentiated
HC11 cells (D), and Noggin (Nogg).
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cancer cells and primary tumors (Clement et al. 1999) and
BMP7 has been reported to be present in different primary
breast cancers (Schwalbe et al. 2003). The mRNA levels of
BMP receptor and ligand are greater in cells with high
metastasic potential (Arnold et al. 1999). However,
BMP2 has been shown to inhibit proliferation in breast
cancer cell lines that express SMAD1 and SMAD4
(Ghosh-Choudhury et al. 2000; Pouliot and Labrie
2002). BMP2 has also been shown to enhance the mi-
gration of MCF7 breast cancer cell line and its over-
expression promotes tumor formation in a breast cancer
xenograft model (Clement et al. 2005). Clearly, more
research is required to understand the role of BMPR1A
in the normal and diseased mammary gland.
Conclusions
Our results suggest that the BMP-BMPR1A pathway, pos-
sibly via SMAD1/5/8, is required in undifferentiated and/or
competent HC11 cells to allow the proper differentiation of
mammary milk-secretory cells. This is the first analysis of
BMPR1A function in mammary epithelial cell differentia-
tion, and our results indicate that the pathway is required
before lactogenic hormone signalling for the production of
beta-casein.
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